Ironwood Pharmaceuticals, Inc. (IRWD) Financial Statements
Ironwood Pharmaceuticals, Inc. (IRWD) reported trailing twelve-month revenue of $389.3M (up 26.2% year on year) and net income of $129.9M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $185.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IRWDIronwood Pharmaceuticals, Inc.Follow IRWD — free
—
Price chart with a free account
- Market cap
- 571.7M
- P/E TTM
- 4.5
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.07 | 0.15 | 0.02 | 0.08 | 0.15 | 0.27 | 0.30 | 0.35 | 0.43 | 0.39 | 0.41 | 0.41 | 0.44 | 0.35 | 0.30 | 0.39 | |
| Gross profit | — | 0.15 | 0.02 | 0.07 | 0.15 | 0.27 | 0.28 | 0.31 | 0.40 | 0.39 | — | — | — | 0.35 | 0.28 | — | |
| Research & development | 0.09 | 0.11 | 0.10 | 0.10 | 0.11 | 0.14 | 0.09 | 0.10 | 0.12 | 0.09 | 0.07 | 0.04 | 0.12 | 0.11 | 0.10 | 0.09 | |
| Operating income | -0.07 | -0.07 | -0.25 | -0.17 | -0.10 | -0.05 | -0.02 | -0.15 | 0.12 | 0.14 | 0.23 | 0.25 | -0.95 | 0.09 | 0.10 | 0.23 | |
| Pre-tax income | -0.06 | -0.07 | -0.27 | — | -0.14 | -0.08 | -0.05 | -0.19 | 0.06 | 0.11 | 0.20 | 0.25 | -0.95 | 0.07 | 0.07 | 0.21 | |
| Income tax | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.33 | 0.08 | 0.08 | 0.06 | 0.05 | 0.08 | |
| Net income | -0.06 | -0.07 | -0.27 | -0.19 | -0.14 | -0.08 | -0.12 | -0.28 | 0.02 | 0.11 | 0.53 | 0.18 | -1.00 | 0.00 | 0.02 | 0.13 | |
| Diluted EPS ($) | -0.65 | -0.68 | -2.35 | -1.39 | -1.00 | -0.56 | -0.78 | -1.85 | 0.14 | 0.66 | 3.21 | 0.96 | -6.45 | 0.01 | 0.15 | 0.77 | |
| Diluted shares (bn) | 0.100 | — | — | — | — | — | — | 0.153 | 0.156 | 0.161 | 0.164 | 0.186 | 0.155 | 0.160 | 0.163 | — |
USD billions · SEC XBRL
Ironwood Pharmaceuticals, Inc. — questions
- What is Ironwood Pharmaceuticals, Inc.'s revenue?
- $389.3M over the twelve months to 2026-06-30, up 26.2% year on year, from its 10-Q and 10-K filings.
- What is Ironwood Pharmaceuticals, Inc.'s net income?
- $129.9M over the twelve months to 2026-06-30.
- What is Ironwood Pharmaceuticals, Inc.'s free cash flow?
- $185.6M over the twelve months to 2026-06-30.
- What are Ironwood Pharmaceuticals, Inc.'s diluted earnings per share?
- $0.77 over the twelve months to 2026-06-30.
Every figure on this page comes from Ironwood Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.